Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
|
| Posted
:
Mon, 09 Nov 2009 11:28:27 GMT |
| Author
:
Simcere Pharmaceutical Group |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
NANJING, China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group
(NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of branded
generic and proprietary pharmaceuticals in China, today announced an agreement
to acquire the manufacturing license in China of Rosuvastatin from Tianjin
Tianda Pharmaceutical Co., Ltd. ("Tianda"). The acquisition of the
manufacturing license will be effected through the acquisition of equity in
Tianda as well as transfer of certain technologies from Tianda. Rosuvastatin
was first marketed by Astrazeneca as Crestor in 2003 and is an effective
statin to treat high cholesterol and related conditions.
Upon completion of the acquisition, Simcere will start manufacturing
Rosuvastatin.
Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere
Pharmaceutical Group commented on the agreement, "We are delighted to join
forces with Tianda to manufacture Rosuvastatin in China. Rosuvastatin has huge
market potential and we believe that with our marketing expertise we can help
more heart disease patients in China benefit from this drug."
Safe Harbor Statement
This press release contains forward-looking statements. These statements
constitute "forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "anticipate," "believe,"
"estimate," "expect," "forecast," "intend," "may," "plan," "project,"
"predict," "should" and "will" and similar expressions. These forward looking
statements are based upon management's current views and expectations with
respect to future events and are not a guarantee of future performance.
Furthermore, these statements are, by their nature, subject to a number of
risks and uncertainties that could cause actual performance and results to
differ materially from those discussed in the forward-looking statements as a
result of a number of factors. Further information regarding these and other
risks is included in Simcere's filings with the U.S. Securities and Exchange
Commission at http://www.sec.gov . Simcere does not undertake any obligation
to update any forward-looking statement, except as required under applicable
law.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading
pharmaceutical company specializing in the development, manufacturing, and
marketing of branded generic and proprietary pharmaceuticals in China. In
recent years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics, and has introduced an
innovative anti-cancer medication Endu, a first-to-market medication Sinofuan,
and first-to-market generics such as Bicun and Anxin. Simcere manufactures and
sells anti-infective medication, anti-cancer medication and stroke management
medication. Simcere concentrates its research and development efforts on the
treatment of diseases with high incidence and/or mortality rates and for which
there is a clear demand for more effective pharmacotherapy such as cancer,
strokes, orthopaedics and infectious diseases. For more information about
Simcere Pharmaceutical Group, please visit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
FNC Blog: Appraisers Working Long-Distance Spells Trouble for Mortgage Industry OXFORD, Miss. -
A mortgage industry trend that requires appraisers to work in unfamiliar
neighborhoods is resulting in serious valuation issues, according to a
new blog posted Sunday, Nov. 22.
FNC’s chief data and analytics officer Dr. Bob Dorsey tackles the issue
Ryan Mallett, Jeremiah Masoli, Shane Vereen and Deunta Williams Announced as Week Twelve Nominees for the AT&T All-America Player of the Week Award
ATLANTA, Nov. 22 /PRNewswire/ -- Four nominees for the AT&T All-America Player of the Week award have been announced after the twelfth week of college football action, and AT&T* is relying on fans to determine who rules the gridiron.
Based on outstanding performa...
Vancouver Label Flaming Angels Celebrates 10th Anniversary
VCAD instructor Miriam Melanson passes along her advice to aspiring designers/I/P
PVancouver, BC (PRWEB) November 22, 2009 -- What has become an institution in the Vancouver Goth scene, humbly began ten years ago as the vision of design school grad, Miriam Melanson. Looking to take her ...
ViSalus Sciences® Launches Initiative to Help Feed Hungry Children in Local Communities
In an Effort to Impact the Lives of Hungy Children Across the World, ViSalus Sets Goal to Donate 100,000+ Healthy Meals through the Body By Vi™ Community Challenge to Local Communities/I/P
PLos Angeles, CA (PRWEB) November 22, 2009 -- At a recent ViSalus Sciences® national co...
Kerio Appoints Industry Veteran Pavel Suk as Vice President of Engineering SAN JOSE, CA -- 11/22/09 --
Kerio Technologies, Inc., a leading provider
of Internet security and messaging solutions, today announced that Pavel
Suk has joined the company's executive management team as vice president of
Engineering. Bringing more..
Leading VAR of New and Refurbished Networking Equipment Launches Network Analysis and Troubleshooting Services
Abacus Solutions delivers Network Services designed to ease the burden off of IT departments. The company boasts a staff of in-house, experienced engineers and an extensive in-stock inventory of new and refurbished networking equipment./I/P
PMarietta, GA (PRWEB) November 22, 2009 -- Ab...
BQDRI and PROJACS INTERNATIONAL sign MOU to support the implementation of sustainability DOHA, Qatar -
BARWA and Qatari Diar Research Institute (BQDRI), that focus on studies
about new knowledge in sustainability and its application, and
|
|
|
|
|
|
|
|
|